Antisense oligodeoxynucleotides to latent membrane protein 1 induce growth inhibition, apoptosis and Bcl-2 suppression in Epstein-Barr virus (EBV)-transformed B-lymphoblastoid cells, but not in EBV-positive natural killer cell lymphoma cells

British Journal of Haematology

Volumn 114, Issue 1, 2001, Pages 84-92

  Noguchi, Toshio ^a   Ikeda, Kazuma ^a   Yamamoto, Kazuhiko ^a   Yoshida, Isao ^a   Ashiba, Atsuko ^a   Tsuchiyama, Junjiro ^a   Shinagawa, Katsuji ^a   Yoshino, Tadashi ^a   Takata, Minoru ^b   Harada, Mine ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Antisense oligodeoxynucleotides; Apoptosis; EBV positive NK cell lymphoma; LMP 1; Proliferation

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; LATENT MEMBRANE PROTEIN 1; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; B LYMPHOBLAST; CELL PROLIFERATION; EPSTEIN BARR VIRUS; GROWTH INHIBITION; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL; LYMPHOMA CELL LINE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS CELL TRANSFORMATION;

APOPTOSIS; BLOTTING, WESTERN; CARRIER PROTEINS; CELL DIVISION; CELL LINE, TRANSFORMED; GENE DELETION; GENE EXPRESSION; HERPESVIRUS 4, HUMAN; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KILLER CELLS, NATURAL; LYMPHOMA, T-CELL; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 0034941574     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02887.x     Document Type: Article

References (46)

1. Posttranslational processing of an Epstein-Barr virus-encoded membrane protein expressed in cells transformed by Epstein-Barr virus
2. The 30-bp deletion variant of Epstein-Barr virus-encoded latent membrane protein-1 prevails in acute infectious mononucleosis
3. Localization of the major NF-kappaB-activating site and the sole TRAF3 binding site of LMP-1 defines two distinct signaling motifs
4. Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease
5. Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation
6. No direct role for Epstein-Barr virus in oral carcinogenesis: A study at the DNA, RNA and protein levels
7. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP-1 domain important for B-lymphocyte transformation: Role in NF-κB activation
8. High prevalence of a 30-base pair deletion in the Epstein-Barr virus (EBV) latent membrane protein 1 gene and of strain type B EBV in Mexican classical Hodgkin's disease and reactive lymphoid tissue
9. Epstein-Barr virus strains with latent membrane protein-1 deletions: Prevalence in the Italian population and high association with human immunodeficiency virus-related Hodgkin's disease
10. Epstein-Barr virus: LMP-1 masquerades as an active receptor
11. Epstein-Barr virus encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2
12. Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein
13. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule
14. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins
15. Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency
16. Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes
17. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death
18. A membrane protein encoded by Epstein-Barr virus in latent growth-transforming infection
19. Bcl-2 is expressed in human natural killer cells and is regulated by interleukin-2
20. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation
21. Tumor necrosis factor receptor associated factor 2 is a mediator of NF-κB activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein
22. Antisense to the Epstein-Barr Virus (EBV)-encoded latent membrane protein 1 (LMP-1) suppresses LMP-1 and bcl-2 expression and promotes apoptosis in EBV-immortalized B cells
23. Epstein-Barr virus and its replication
24. Epstein-Barr virus and its replication
25. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the C-Jun N-terminal kinase cascade
26. Epstein-Barr virus mediated B-cell proliferation is dependent upon latent membrane protein 1, which stimulates an activated CD40 receptor
27. Epstein-Barr virus latent membrane protein-1 oncogene deletions: Correlations with malignancy in Epstein-Barr virus-associated lymphoproliferative disorders and malignant lymphomas
28. Treatment outcome and prognostic factor for primary nasal lymphoma
29. Nasopharyngeal carcinoma: The Epstein-Barr virus association
30. Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus
31. Prevalence of Epstein-Barr viral sequences and EBV LMP-1 oncogene deletions in Burkitt's lymphoma from Pakistan: Epidemiological correlations
32. Immortalizing genes of Epstein-Barr virus
33. Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases
34. Epstein-Barr virus LMP-1 induction of the epidermal growth factor receptor is mediated through a TKAF signaling pathway distinct from NF-κB activation
35. The Epstein-Barr virus transforming protein LMP-1 engages signaling proteins for the tumor necrosis factor receptor family
36. Bcl-2 but not its Epstein-Barr virus-encoded homologue, BHRF-1, is commonly expressed in posttransplantation lymphoproliferative disorders
37. The EBV-encoded LMP-1 protein inhibits p53-triggered apoptosis but not growth arrest
38. Epstein-Barr virus
39. Upregulation of bcl-2 by the Epstein-Barr virus latent-membrane protein LMP-1: A B-cell-specific response that is delayed relative to NF-κB activation and to induction of cell surface markers
40. Characterization of LMP-1′S association with TRAF1, TRAF2, and TRAF3
41. Transcription of Epstein-Barr virus in latently infected, growth transformed lymphocytes
42. Nasal lymphomas in Japan: A high prevalence of Epstein-Barr virus type A and deletion within the latent membrane protein gene
43. Epstein-Barr virus nuclear proteins EBNA-3A, and EBNA-3C are essential for B-lymphocyte growth tranformation
44. Characterization of a novel human natural killer-cell line (NK-YS) established from natural killer cell lymphoma/leukemia associated with Epstein-Barr Virus infection
45. Epstein-Barr virus latent-membrane protein (LMP-1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP-1 cooperatively induce CD23
46. Detection of Epstein-Barr virus genome in natural-killer-like cell line, YT